../wp-content/uploads/2019/03/20181220-Phase-1-TG4001-FR-1.pdf
Catégorie : 2018
Transgene présente son calendrier de communication financière pour 2019
20181217-CP-Agenda-Financier-2019
Transgene annonce ses prochaines rencontres avec les investisseurs
20181205-CP-Investors-Meeting-agenda-T1-2019.pdf
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux… Poursuivre la lecture Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Transgene participe au salon Actionaria les 22 et 23 novembre 2018 à Paris
20181115 CP Actionaria du 22 et 23 novembre 2018
Transgene – Résultats positifs de l’essai clinique de Phase 1 de TG1050 dans l’hépatite B chronique présentés à l’AASLD Liver Meeting 2018
20181112 PR TG0150 Phase 1 data combi AASLD FR
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation
Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden
